According to the results of the first half of 2018, imports of finished mediсinal drugs to Russia amounted to 244.3 billion rubles (in prices of release for free circulation). Deliveries of in-bulk products during the same period reached 52 billion rubles.
Year over year growth comparing to the same period in 2017 when calculating in rubles amounted to 2% for finished forms, the supply of bulk products increased by 22% for the year. The total volume of medicines imported since the beginning of the year increased in ruble terms by 5%.
The natural volume of imports of finished medicines for the period January-June of this year is 878.7 million packs, which is 7% less than in the same period in 2017. In-bulk deliveries for the period amounted to 2.12 billion minimal dosing units (MDU). The dynamics feels better (relative to the FMP), but retains a negative value (-0.4%). The total volume of supplies for all forms for the first half of the year was 18.5 billion MDU, long-term dynamics therefore is also in the red (-4%).
Among the top 20 finished medicines, leading in terms of imports in the first half of the year, antiviral drugs active against HIV show the maximum dynamics: Tivicay (for the year the ruble volume of deliveries increased 20 times) and Eviplera (deliveries increased 3 times). As regards in-bulk production, the two top positions, both in share and in terms of dynamics, are Revlimid formulations (imports in rubles increased more than 200 times during the year) and Concor (shipments increased 16 times).